

17\ 01 \2014



Ministerstwo Nauki
i Szkolnictwa Wyższego

Industry involvement in H2020 - health research perspective



Polish perspective



National Reserach Programme

**New energy-related
technologies**

**Diseases of affluence,
new medicines
and regenerative medicine**

**Advanced information,
telecommunications
and mechatronic
technologies**


New materials technologies

**Natural environment,
agriculture and forestry**

**Poland's social and
economic development
in the context of
globalising markets**

State security and defence

Smart specialisation in Poland (draft)





EU perspective



HORIZON 2020

- ✓ the biggest EU research and innovation programme ever, with a budget of over 77 billion € for the seven years of duration of the programme (2014-2020)
- ✓ responding to the economic crisis to invest in future jobs and growth
- ✓ addressing people's concerns about their livelihoods, safety and environment
- ✓ placing more emphasis than ever on making sure that Europe's great ideas get from the laboratory to the market
- ✓ strengthening the EU's global position in research, innovation and technology

Horizon 2020

**Excellent
Science**

24 441,1 mln €

**Industrial
Leadership**

17 015,5 mln €

**Societal
Challenges**

29 679 mln €

**Health, demographic
change & well-being**

7 471,8 mln €



Involvement of industry in H2020

- ✓ Horizon 2020 is designed to bring business into the research and innovation chain throughout its various components

Art. 25

Public-private partnerships


1. Horizon 2020 may be implemented through public-private partnerships where all the partners concerned commit to supporting the development and implementation of pre- competitive research and of innovation activities of strategic importance to the Union's competitiveness and industrial leadership or to addressing specific societal challenges (...).



Public-private partnerships in H2020 – why?

- ✓ to facilitate prioritisation of research and innovation in line with Europe 2020 objectives and industry needs
- ✓ to solve problems together with industry
- ✓ to strongly commit industry to join objectives

Public-private partnerships in H2020 – how?




JTIs in H2020

JTI	Objectives
<u>Innovative Medicines Initiative 2</u>	New treatments and medicines (e.g. against antimicrobial resistance)
Fuel Cells and Hydrogen 2	New ways to store and transport energy
Clean Sky 2	Cleaner, quieter aircraft
Bio-based Industries	New bio-products to replace oil (e.g. sustainable biofuels)
Electronic components and systems	Boost electronics manufacturing capabilities
Shift2Rail	Innovative rail product solutions


Polish participation in IMI1 – state of play

Call	Acronym	Entity	Funding
1	PROTECT	Poznan University of Medical Sciences	66 253,00 €
1	U-BIOPRED	Uniwersytet Jagiellonski	208 954,00 €
2	EHR4CR	Medical University of Warsaw	209 600,00 €
3	EUPATI	The Employers' Union of Innovative Pharmaceutical Companies INFARMA	-
8	ENABLE	National Medicines Institute	381 000,00 €

Polish participation in IMI1 – state of play




Polish participation in IMI1 – state of play




IMI2 – work in progress

Accepted by EU Council (December 2013)



Analysed by EU Parliament (currently)



Estimated approval – April 2014

17 \ 01 \ 14



Ministerstwo Nauki
i Szkolnictwa Wyższego

Thank you for your attention!

Mateusz Gaczyński
Director of the Department of Strategy
Ministry of Science and Higher Education

sekretariat.ds@mnisw.gov.pl